Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$9.17
-2.0%
$9.11
$0.06
$14.93
$7.01M0.98559,538 shs12,224 shs
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
$1.16
$0.16
$3.32
$330K1.6611,347 shs107,749 shs
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$3.94
$1.56
$21.96
$3.47M1.13617,505 shs243,634 shs
PolarityTE, Inc. stock logo
PTE
PolarityTE
$0.37
$0.20
$1.90
$1.78M1.15249,591 shs8.50 million shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$0.72
+10.6%
$0.72
$0.36
$737.44
$2.63M0.72.03 million shs2.02 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
+1.63%+5.76%+2.41%+2.41%-73.93%
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
0.00%0.00%0.00%0.00%-91.10%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00%0.00%0.00%+22.89%-76.22%
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00%0.00%0.00%0.00%0.00%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-3.70%-27.78%-18.74%-51.13%-99.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
1.2143 of 5 stars
3.50.00.00.01.10.00.0
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/AN/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
1.862 of 5 stars
3.02.00.00.02.00.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
3.00
Buy$275.002,897.60% Upside
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
0.00
N/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00
N/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00
N/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
2.00
Hold$350.0048,578.72% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$146K48.01N/AN/A$0.20 per share45.87
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/A($8.29) per shareN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$122K0.00N/AN/A$0.02 per share0.00
PolarityTE, Inc. stock logo
PTE
PolarityTE
$810K0.00N/AN/A$2.30 per share0.00
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/A$38.99 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%N/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$1.79M-$823.47N/AN/AN/AN/A-227.93%-56.46%8/18/2025 (Estimated)

Latest ONVO, AIM, WINT, KRBP, and PTE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.05
0.75
0.75
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/A
0.16
0.22
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/A
0.72
1.72
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/A
4.11
4.11
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/A
0.25
0.25

Institutional Ownership

CompanyInstitutional Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
12.02%
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
10.91%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
8.23%
PolarityTE, Inc. stock logo
PTE
PolarityTE
11.75%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
29.33%

Insider Ownership

CompanyInsider Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.02%
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
20.59%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
3.72%
PolarityTE, Inc. stock logo
PTE
PolarityTE
5.40%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
20764,00068.74 millionNot Optionable
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
601.57 million1.22 millionNot Optionable
Organovo Holdings, Inc. stock logo
ONVO
Organovo
201.70 million14.79 millionOptionable
PolarityTE, Inc. stock logo
PTE
PolarityTE
427.38 million6.98 millionOptionable
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
303.66 million3.65 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AIM ImmunoTech stock logo

AIM ImmunoTech NYSE:AIM

$9.17 -0.19 (-1.99%)
Closing price 03:58 PM Eastern
Extended Trading
$9.17 0.00 (-0.04%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Kiromic BioPharma stock logo

Kiromic BioPharma NASDAQ:KRBP

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Organovo stock logo

Organovo NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

PolarityTE stock logo

PolarityTE NASDAQ:PTE

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Windtree Therapeutics stock logo

Windtree Therapeutics NASDAQ:WINT

$0.72 +0.07 (+10.62%)
Closing price 03:58 PM Eastern
Extended Trading
$0.68 -0.04 (-5.01%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.